Trial Profile

An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nipocalimab (Primary)
Indications Myasthenia gravis
Focus Adverse reactions
Sponsors Momenta Pharmaceuticals

Most Recent Events

03 Jun 2023 Results assessing study feasibility assessments presented at the 24th Annual Congress of the European League Against Rheumatism.
14 Nov 2022 Study feasibility assessments involving evaluating results from the phase 2 placebo-controlled trial Vivacity-MG presented at the ACR Convergence 2022
29 Apr 2021 This trial has been discontinued in Germany (End Date: 09 Dec 2020), according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com